OREGA presents its first-in-class CD39 checkpoint inhibitor at the AACR meeting

AlizeePharma_actu
Alizé Pharma: positive results from its Phase II clinical trial in Prader-Willi Syndrome
26 April 2016
Graphtys_actu
GRAFTYS strengthens its management and operations
31 March 2016

OREGA presents its first-in-class CD39 checkpoint inhibitor at the AACR meeting

Orega_actu

OREGA Biotech presented preclinical data on IPH52, a new humanized antibody targeting the CD39 immune checkpoint.